Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms
Niraparib failed to meet the prespecified efficacy end point for response. However, clinical benefit was suggested in a proportion of patients who had a confirmed mBAP1, supporting further investigation.
Authors
- Gayathri Srinivasan
- Julia Close (ORCID: https://orcid.org/0000-0002-7649-0320)
- Nkiruka Ezenwajiaku
- Thomas J. George (ORCID: https://orcid.org/0000-0002-6249-9180)
- Merry Jennifer Markham (ORCID: https://orcid.org/0000-0003-3567-3494)
- Robert Hromas (ORCID: https://orcid.org/0000-0002-1916-6276)
- Dennie V. Jones (ORCID: https://orcid.org/0000-0001-8207-2590)
- Karen Daily (ORCID: https://orcid.org/0000-0002-3218-9739)
- Steven Staal
- Sherise C. Rogers (ORCID: https://orcid.org/0000-0002-4886-3169)
- Martina Murphy
- David L. DeRemer (ORCID: https://orcid.org/0000-0002-2207-9552)
- Brian Hemendra Ramnaraign (ORCID: https://orcid.org/0000-0003-4051-4551)
- Peter J. Hosein (ORCID: https://orcid.org/0000-0001-8537-6397)
- Carmen J. Allegra (ORCID: https://orcid.org/0000-0001-6402-2709)
- Derek Li
- Jonathan Alexander Chatzkel
- Montaser Shaheen (ORCID: https://orcid.org/0009-0006-1542-2267)
- Ji‐Hyun Lee (ORCID: https://orcid.org/0000-0001-6420-5150)
- Zhongyue Zhang
Institutions
- University of Miami (US)
- University of Florida Health (US)
- University of Florida (US)
- Sylvester Comprehensive Cancer Center (US)
- UF Health Cancer Center
- The University of Texas at San Antonio (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1200/po-24-00406
- Citations
- 11
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.11
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- FibroGen
- Florida Department of Health
- Florida Breast Cancer Foundation
- Genentech
- University of Florida Health
- National Cancer Institute